More Than 5 Million US Adults Could Benefit From Lp(a)-Targeted Therapies

Why It Matters

Identifying a sizable eligible population highlights a major unmet therapeutic need and could translate into tens of thousands of avoided heart attacks and strokes, reshaping secondary‑prevention strategies.

Key Takeaways

• 5.3 million U.S. adults with ASCVD have Lp(a) ≥70 mg/dL.
• 10‑30% risk reduction could avert up to 368 k events in five years.
• Current lipid drugs do not lower Lp(a), leaving residual risk.
• Wider Lp(a) testing is essential to capture high‑risk patients.

Pulse Analysis

Lipoprotein(a), or Lp(a), has long been recognized as a genetically determined lipid particle that drives both atherogenesis and thrombosis. Unlike LDL‑C, its concentration is largely unaffected by statins, PCSK9 inhibitors, or ezetimibe, leaving a sizable residual risk in patients already on optimal lipid‑lowering regimens. The 2026 ACC/AHA Dyslipidemia Guideline now advises a one‑time Lp(a) measurement for every adult, reflecting growing consensus that the biomarker should be integrated into routine cardiovascular risk assessment. Yet real‑world testing rates remain low, and many high‑risk individuals are missed.

The recent ACC.26 presentation leveraged NHANES data from the early 1990s, re‑weighted to mirror today’s demographic profile, to estimate that roughly 5.3 million U.S. adults with established ASCVD carry Lp(a) levels of 70 mg/dL or higher. Applying a secondary‑prevention risk model, researchers projected a 5‑year recurrent event rate of 23 percent, equating to 1.2 million events without intervention. Simulated relative risk reductions of 10‑30 percent—consistent with phase‑3 trial targets—translate into 123 000 to 368 000 preventable events over five years, or 25 000‑74 000 fewer heart attacks or strokes each year.

If phase‑3 outcomes for pelacarsen (Novartis) and olpasiran (Amgen) confirm these efficacy signals, Lp(a)‑targeted therapy could become the first disease‑modifying option for a population that has been therapeutically orphaned. Payers will likely evaluate cost‑effectiveness based on the projected event reductions, while clinicians will need clear pathways for identifying eligible patients through systematic Lp(a) screening. The analysis also underscores a policy opportunity: expanding reimbursement for Lp(a) testing could accelerate uptake, improve risk stratification, and ultimately generate substantial public‑health savings. As the data mature, the cardiology community will watch closely for guideline revisions that embed Lp(a) management into standard secondary‑prevention protocols.